Blood-pressure-lowering Effect of Carvedilol Vs Nitrendipine in Geriatric Hypertensives

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1990 Jan 1

PMID 1974510

Citations 5

Authors

B Kronig

L Widmann

C Staiger

M Machwirth

U Stienen

M Hennig

Affiliations

Soon will be listed here.

Abstract

Carvedilol and nitrendipine were given for 12 weeks in a double-blind study to 81 elderly patients (greater than or equal to 60 years) with essential hypertension. The effects on blood pressure were measured (Riva Rocci) before medication and after 2 h with the patient in a lying and standing position after 4 weeks of placebo therapy as well as after 4, 8 and 12 weeks of treatment. Carvedilol (25 mg/o.d.) reduced blood pressure measured in the supine and erect position very successfully, similar to the reduction achieved with nitrendipine (20 mg/o.d.), without influencing the pulse rate. Both substances were well tolerated. Carvedilol is an alternative substance for lowering high blood pressure in elderly hypertensive patients.

Citing Articles

A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.

Widmann L, Zulsdorf B, Hennig M, Lang P Eur J Clin Pharmacol. 1993; 45(2):95-100.

PMID: 8223847 DOI: 10.1007/BF00315487.

Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Morgan T Clin Pharmacokinet. 1994; 26(5):335-46.

PMID: 7914479 DOI: 10.2165/00003088-199426050-00002.

Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

McTavish D, Sorkin E Drugs. 1993; 45(2):232-58.

PMID: 7681374 DOI: 10.2165/00003495-199345020-00006.

Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Wendt T Clin Investig. 1992; 70 Suppl 1:S93-7.

PMID: 1350491 DOI: 10.1007/BF00207618.

Antihypertensive profile of carvedilol.

Meyer-Sabellek W, Agrawal B Clin Investig. 1992; 70 Suppl 1:S43-52.

PMID: 1350484 DOI: 10.1007/BF00207611.

References

Messerli F, Ventura H, Dunn F, Glade L, Frohlich E . Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet. 1983; 2(8357):983-6. DOI: 10.1016/s0140-6736(83)90977-7. View

. Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension. 1985; 7(3 Pt 1):457-68. DOI: 10.1161/01.hyp.7.3_pt_1.457. View

Lamy P . Potential adverse effects of antihypertensive drugs in the elderly. J Hypertens Suppl. 1988; 6(1):S81-5. View

Buhler F, Distler A, LARAGH J, Tourkantonis D, Valdes G, Weber M . Place of calcium antagonists in antihypertensive therapy: introduction and round-table discussion. J Cardiovasc Pharmacol. 1984; 6 Suppl 7:S929-32. View

Kannel W, Gordan T . Evaluation of cardiovascular risk in the elderly: the Framingham study. Bull N Y Acad Med. 1978; 54(6):573-91. PMC: 1807497. View